Literature DB >> 23334525

Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging.

Adriane Gröger1, Benjamin Bender, Isabel Wurster, Grzegorz Lukasz Chadzynski, Uwe Klose, Daniela Berg.   

Abstract

OBJECTIVES: Degeneration of dopaminergic neurons in the substantia nigra (SN) pars compacta is the primary cause of idiopathic Parkinson's disease (iPD). In early stages of disease in particular, presentation of symptoms is non-specific leading to difficulties in differentiating between iPD and atypical parkinsonian syndromes (aPS). The aim of this study was to evaluate the feasibility of three-dimensional magnetic resonance spectroscopic imaging (MRSI) of the SN region for differentiation between iPD and aPS.
METHODS: 20 patients with iPD, 10 with aPS and 22 controls were examined on a 3 T MR scanner using three-dimensional MRSI with a voxel size of 0.252 ml and an echo time of 30 ms. Excitation volume was positioned in such a way that in each hemisphere 1 voxel defines the rostral and 1 voxel the caudal SN region. Using a fully automatic spectra evaluation, the metabolite ratios of N-acetyl aspartate/creatine (NAA/Cr) were calculated.
RESULTS: In all cases spectra with good quality were obtained. Differences in rostral to caudal NAA/Cr ratios were significant between controls and iPD patients, as well as between iPD and aPS patients (p<0.001 for both). For controls, rostral NAA/Cr was greater than caudal, whereas in iPD patients this ratio was reversed. aPS patients showed similar ratios as controls.
CONCLUSIONS: Typical reversed rostral to caudal NAA/Cr ratios in iPD patients suggests that they could be linked to specific pathology of neuronal loss in the SN pars compacta. Therefore, the results suggest that MRSI may support the differential diagnosis of patients with clinically unclassifiable parkinsonian syndromes who do not yet fulfil the established clinical criteria.

Entities:  

Keywords:  MRS; Parkinson's Disease

Mesh:

Year:  2013        PMID: 23334525     DOI: 10.1136/jnnp-2012-302699

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

Review 1.  Metabolic Imaging in Humans.

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Top Magn Reson Imaging       Date:  2016-10

Review 2.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

3.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

Review 4.  The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 5.  Preconditioning as a potential strategy for the prevention of Parkinson's disease.

Authors:  Mojtaba Golpich; Behrouz Rahmani; Norlinah Mohamed Ibrahim; Leila Dargahi; Zahurin Mohamed; Azman Ali Raymond; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-04-03       Impact factor: 5.590

6.  Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.

Authors:  Adriane Gröger; Rupert Kolb; Rita Schäfer; Uwe Klose
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

7.  Eryptosis as a marker of Parkinson's disease.

Authors:  Etheresia Pretorius; Albe C Swanepoel; Antoinette V Buys; Natasha Vermeulen; Wiebren Duim; Douglas B Kell
Journal:  Aging (Albany NY)       Date:  2014-10       Impact factor: 5.682

Review 8.  Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update.

Authors:  Giovanni Rizzo; Stefano Zanigni; Roberto De Blasi; Daniela Grasso; Davide Martino; Rodolfo Savica; Giancarlo Logroscino
Journal:  Parkinsons Dis       Date:  2016-09-28

Review 9.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

Review 10.  Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?

Authors:  Rosella Ciurleo; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.